中国临床实用医学
中國臨床實用醫學
중국림상실용의학
CHINA CLINICAL PRACTICAL MEDICINE
2008年
3期
36-37
,共2页
红斑狼疮%系统性%总胆红素
紅斑狼瘡%繫統性%總膽紅素
홍반랑창%계통성%총담홍소
Lupus erythematosus%Systemic%Total bilirubin
目的 探讨系统性红斑狼疮(SLE)患者血清中总胆红素(TBIL)水平与疾病活动程度的关系与意义.方法 用重氮盐改良J-G法检测和比较分析54例SLE患者和50名健康人血清TBIL的水平.结果 SLE患者组血清TBIL水平[(9.80 ±4.98)μmol/L]比健康对照组[(13.54±5.20)μmol/L]明显降低(P＜0.001);经糖皮质激素治疗后血清TBIL浓度[(12.83±5.18)μmol/L]与治疗前[(5.79±3.73)μmol/L]相比,差异有显著意义(P＜0.001);活动期SLE血清TBIL水平[(5.93±3.78)μmol/L]低于非活动期[(8.93±4.18)μmol/L(P＜0.05);蛋白尿组[(6.64±3.56)μmol/L]低于非蛋白尿组[(9.30±4.36)μmol/L](P＜0.05);血管炎组[(6.32±4.31)μmol/L]和非血管炎组[(9.96±5.03)μmol/L]之间相比有明显显著意义(P＜0.001).结论 TBIL可能参与SLE的发病机制,TBIL的血清水平可作为反映SLE活动程度、肾脏损害以疾病进展或改善的指标.
目的 探討繫統性紅斑狼瘡(SLE)患者血清中總膽紅素(TBIL)水平與疾病活動程度的關繫與意義.方法 用重氮鹽改良J-G法檢測和比較分析54例SLE患者和50名健康人血清TBIL的水平.結果 SLE患者組血清TBIL水平[(9.80 ±4.98)μmol/L]比健康對照組[(13.54±5.20)μmol/L]明顯降低(P＜0.001);經糖皮質激素治療後血清TBIL濃度[(12.83±5.18)μmol/L]與治療前[(5.79±3.73)μmol/L]相比,差異有顯著意義(P＜0.001);活動期SLE血清TBIL水平[(5.93±3.78)μmol/L]低于非活動期[(8.93±4.18)μmol/L(P＜0.05);蛋白尿組[(6.64±3.56)μmol/L]低于非蛋白尿組[(9.30±4.36)μmol/L](P＜0.05);血管炎組[(6.32±4.31)μmol/L]和非血管炎組[(9.96±5.03)μmol/L]之間相比有明顯顯著意義(P＜0.001).結論 TBIL可能參與SLE的髮病機製,TBIL的血清水平可作為反映SLE活動程度、腎髒損害以疾病進展或改善的指標.
목적 탐토계통성홍반랑창(SLE)환자혈청중총담홍소(TBIL)수평여질병활동정도적관계여의의.방법 용중담염개량J-G법검측화비교분석54례SLE환자화50명건강인혈청TBIL적수평.결과 SLE환자조혈청TBIL수평[(9.80 ±4.98)μmol/L]비건강대조조[(13.54±5.20)μmol/L]명현강저(P＜0.001);경당피질격소치료후혈청TBIL농도[(12.83±5.18)μmol/L]여치료전[(5.79±3.73)μmol/L]상비,차이유현저의의(P＜0.001);활동기SLE혈청TBIL수평[(5.93±3.78)μmol/L]저우비활동기[(8.93±4.18)μmol/L(P＜0.05);단백뇨조[(6.64±3.56)μmol/L]저우비단백뇨조[(9.30±4.36)μmol/L](P＜0.05);혈관염조[(6.32±4.31)μmol/L]화비혈관염조[(9.96±5.03)μmol/L]지간상비유명현현저의의(P＜0.001).결론 TBIL가능삼여SLE적발병궤제,TBIL적혈청수평가작위반영SLE활동정도、신장손해이질병진전혹개선적지표.
Objective To investigate the relationship between serum level of TBIL(total bilirubin) and the disease activity of systemic lupus erythematosua (SLE). Methods Serum level of TBIL of 50 controls and 54 SLE patients were measured by Jendrassik and Grof method. Results Significantly decreased serum level of TBIL was found in SLE patients as compared to that in healthy controls [(9.80±4.98)μmol/L vs. (13.54± 5.20)μmol/L] (P＜ 0.001) ; Serum level of TBIL was lower before treatment(5.79±3.73)μmol/L than after treatment(12.83±5.18)μmoL/L(P＜0.001);Serum level of TBIL was lower in active patients than those with inactive disease, namely[(5.93±3.78)μmol/L vs. (8.93±4.18) μmol/L(P＜0.05)]; Serum level of TBIL was decreased in patients with proteinuria[(6.64±3.56)μmol/L vs. (9.30±4.36)μmoL/L] (P ＜ 0.05);Serum level of TBIL was lower in patients with vasculitis [(6.32±4.31)μmoL/L vs. (9.96±5.03)μmol/L] (P ＜0.001). Conclusion The present data suggests that TBIL may be involved in the pathogenesis of SLE and serum TBIL level may be a marker of disease activity, renal damage, disease progression and amelioration in SLE.
